| Literature DB >> 31768406 |
Aaron M Wendelboe1, Richard Mathew2, Tana Chongsuwat2, Elizabeth Rainwater2,3, Mark A Wendelboe2, Elizabeth Wickersham2, Ann F Chou2.
Abstract
Opioid use, abuse, and associated mortality have reached an epidemic level. In some states, cannabis is being used to treat chronic pain. To examine the hypothesis that medical marijuana legislation may reduce adverse opioid-related outcomes if patients substitute cannabis for opioids for pain management, we conducted a clinical inquiry (Clin-IQ). We searched Ovid MEDLINE, Ovid MEDLINE In-Process, and Embase for studies using the search terms marijuana, cannabis, legal, marijuana smoking, medical marijuana, opioid-related disorders, cannabis use, medical cannabis, legal aspect, and opiate addiction. We included population-based articles published from January 1, 2012, through December 5, 2018, that assessed the relationship between marijuana use and decriminalization and the aforementioned opioid-related outcomes. Ten peer-reviewed studies met the inclusion criteria; 3 cross-sectional studies, 6 ecologic studies (ie, using aggregate data), and 1 retrospective cohort study. Eight studies reported associations between policies decriminalizing marijuana and reduced prescription opioid use, 1 study was inconclusive, and the retrospective cohort study reported an increase in adverse opioid-related outcomes. These results should be interpreted with caution given limitations associated with the studies' design. Results demonstrating association between marijuana decriminalization and opioid-related outcomes are mixed. Longitudinal studies are needed, and further analysis of this policy should continue to be tracked.Entities:
Keywords: analgesic; cannabis; decriminalization; ecologic analysis; epidemiology; medical marijuana; opioid
Year: 2019 PMID: 31768406 PMCID: PMC6827842 DOI: 10.17294/2330-0698.1704
Source DB: PubMed Journal: J Patient Cent Res Rev ISSN: 2330-068X